I le taimi nei, o loʻo iai pea le COVID-19 i tulaga faʻamaʻi i le lalolagi atoa. O le faʻatonuga o Delta ma Omicron variants ua faʻateleina, e mafua ai le faʻaauau pea o le faʻaleleia o latou gafatia faʻasalalau. I le lotolotoi o galu faifai pea o le COVID-19, faʻaopoopo i le COVID-19 tui, o le atinaʻeina o vailaʻau faʻamaʻi COVID-19 ma le vave, faigofie ma le fou o suʻega, ua avea foi ma se manaʻoga fou mo le puipuia ma le puleaina o faʻamaʻi. O le Viva Biotech Holdings ma le XLement, o lo'o teu fa'afaigaluegaina ma fa'atumauina e le Viva BioInnovator, o lo'o fa'amaoni i le gaosiga o vaila'au fa'afofoga COVID-19 ma su'ega fa'ama'i, e fesoasoani i le tau faasaga i le fa'ama'i COVID-19.

Langhua Pharmaceutical saini maliliega ma MPP e gaosia ai vailaʻau faʻamaʻi ole COVID-19 molnupiravir.

Ian 2022, na faasilasila mai ai e le Vailaau Pateni Vailaau (MPP) ua sainia maliega ma le tele o kamupani gaosi oloa e aofia ai le Zhejiang Langhua Pharmaceutical Co., Ltd (Langhua Pharmaceutical), le lala o Viva biotech holdings (Viva Biotech (01873.HK)) mo le gaosiga o le gutu COVID-19 antiviral vailaʻau molnupiravir ma tuʻuina atu i 105 maualalo-ma-ogatotonu-tupe maua (LMICs) e faafaigofie ai le taugofie o avanoa molnupiravir mo le molnupiravir ma lagolago i le lotoifale puipuia ma pulea faamai. E lima kamupani o le a taulaʻi i le gaosiga o mea mataʻutia, 13 kamupani o le a gaosia uma mea faʻapitoa ma vailaʻau faʻamaeʻa ma kamupani e 9 o le a gaosia le vailaʻau maeʻa.

Ole Vailaau Pateni Fa'afofoga (MPP) ose fa'alapotopotoga fa'alesoifua maloloina lautele o lo'o lagolagoina e Malo Aufaatasi o lo'o galulue e fa'ateleina le avanoa i, ma fa'afaigofie le atina'eina o vaila'au fa'asao ola mo atunu'u maualalo ma feololo tupe maua. O le MPP ma le MSD, le igoa tau fefa'ataua'iga a Merck & Co., Inc Kenilworth NJ USA na sainia se maliega tau laisene ia Oke 2021. I lalo o aiaiga o le maliliega, MPP, e ala i le laisene na tu'uina atu e MSD, o le a fa'atagaina e fa'aopoopo laisene e le fa'apitoa. sublicences i tagata gaosi oloa ("MPP Laisene") ma fa'avasega le fale gaosi oloa mo le tu'uina atu o molnupiravir fa'amautinoa lelei i atunu'u o lo'o aofia i le Laisene MPP, i lalo o le fa'atagaga fa'alotoifale.

Molnupiravir (MK-4482 ma EIDD-2801) o se su'esu'ega, tu'u gutu fa'ata'ita'iga o le malosi ribonucleoside analog e taofia ai le toe faia o le SARS-CoV-2 (le mafua'aga o le COVID-19). Molnupiravir o loʻo atiaʻe e le MSD i faiga faʻapaʻaga ma Ridgeback Biotherapeutics, o le vailaʻau faʻamaʻi tuʻu muamua o loʻo avanoa mo togafitiga COVID-19. Fa'amaumauga mai le Vaega 3 MOVE-OUT na fa'aalia ai o togafitiga vave ma le molnupiravir na matua fa'aitiitia ai le lamatiaga o le falema'i po'o le oti i tulaga maualuga, tagata matutua e le'i faia tui ma le COVID-19.

Fai mai le MPP, o kamupani na ofoina atu le sublicence na faʻaalia ma le manuia lo latou gafatia e faʻamalieina manaʻoga a le MPP e fesoʻotaʻi ma le gafatia o le gaosiga, tausisia o tulafono faatonutonu, ma le mafai ona ausia tulaga faʻavaomalo mo vailaʻau faʻamautinoa lelei. O le faʻatagaina na tuʻuina atu i le Langhua Pharmaceutical e le MPP o loʻo faʻatusalia ai se faʻamaoniga maualuga ma le faʻaalia i lona faʻagasologa o le atinaʻeina ma le faʻalauteleina o APIs, faʻaauau le tuʻuina atu, GMP ma le EHS system.

Xlement's COVID-19 Su'ega Pusa Su'esu'ega a le Matagaluega o Saienisi ma Tekonolosi a le Malo o Saina ma le Manuia.

I le aso 2 o Mati, 2022, na maua ai e Xlement, o le NanoSPR biochip ma meafaigāluega biotech kamupani sa teu fa'afaigaluega muamua ma fa'a'au e Viva BioInnovator, le fa'asilasilaga o le pasia o le iloiloga o fa'atinoga mai le Matagaluega o Saienisi ma Tekonolosi a le Malo o Saina. O lana poloketi "R&D ma Mass Production of NanoSPR COVID-19 Particle Test Kit" o se tasi lea o poloketi autu o le "Public Safety Risk Prevention and Control and Emergency Response Technology and Equipment" lea e tautuaina se vaega taua i le COVID-19- su'esu'ega fa'asaienisi feso'ota'i o lo'o fa'aauau i Saina. Faatasi ai ma lona pasi manuia i le asiasiga, Xlement's COVID-19 Test Kit ua faʻamaonia foi e le European Union CE mo le gaosiga tele i le lumanaʻi ma o le a faʻaaogaina vave.

O le fa'aogaina i luga o tekinolosi fa'apitoa NanoSPR chip, na fausia ai e Xlement le pusa fa'ata'ita'i mo vaega o le COVID-19, lea e fa'ataga ai le su'ega e tasi o le tele o siama fa'ama'i mo fa'ata'ita'iga e 96 i totonu ole 15 minute, ma o le ma'ale'ale e latalata ile su'ega o se antigen e tasi. O lenei metotia o loʻo faʻaalia ai le lelei tele pe a faʻatusatusa i vailaʻau faʻataʻitaʻiga o vailaʻau faʻamaʻi viral: e mafai ona faʻaaogaina mo le suʻega a le tagata lava ia i le fale, e faʻapuʻupuʻu tele le taimi o suʻega, ma faʻaitiitia ai le tau o suʻega suʻega ma galuega. Faatasi ai ma le tele o le faʻaaogaina o le NanoSPR tekonolosi i le COVID-19 suʻega na atiaʻe e Xlement, matou te faʻamoemoe e vaʻaia le sili atu ona faigofie suʻesuʻega o masalomia faʻataʻitaʻiga ma luga o le nofoaga suʻesuʻe vave i le tele.

OA MEA E AVEA MAI LENEI TUSI:

I le aso 2 o Mati, 2022, na maua ai e Xlement, o le NanoSPR biochip ma meafaifaaili biotech kamupani faʻapipiʻi muamua ma faʻapipiʻiina e le Viva BioInnovator, le faʻaaliga o le pasia o le iloiloga o faʻatinoga mai le Matagaluega o Saienisi ma Tekonolosi a le Malo o Saina.
Under the terms of the agreement, MPP, through the license granted by MSD, will be permitted to further license non-exclusive sublicences to manufacturers (“MPP Licence”) and diversify the manufacturing base for the supply of quality-assured molnupiravir to countries covered by the MPP Licence, subject to local regulatory authorization.
I le lotolotoi o galu faifai pea o le COVID-19, faʻaopoopo i le COVID-19 tui, o le atinaʻeina o vailaʻau faʻamaʻi COVID-19 ma faʻataʻitaʻiga vave, faigofie ma fou suʻega ua avea foi ma se manaʻoga fou mo le puipuia ma le puleaina o faʻamaʻi.